Merck Announces FDA Acceptance of New Drug Application for an Investigational Tablet Formulation of the Antifungal NOXAFIL® (posaconazole)
Dateline City:
WHITEHOUSE STATION N.J.
WHITEHOUSE STATION N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that its New Drug Application for an investigational,
tablet formulation of the company's antifungal agent, NOXAFIL®
(posaconazole), has been accepted for review by the U.S. Food and Drug
Administration (FDA).
Language:
English
Contact HTML:
...
Source: Merck.com - Product News - April 10, 2013 Category: Drugs & Pharmacology Authors: hq_site_admin Tags: Prescription Medicine News Corporate News Source Type: news
Merck to Present New Data on VICTRELIS® (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM / 2013 EASL Annual Meeting
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--
Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
announced today that two analyses of VICTRELIS (boceprevir) and data
from Phase II studies of two of Merck’s investigational medicines for
chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir
(MK-7009), will be presented at the 2013 International Liver Congress
(EASL) Annual Meeting. The meeting will take place in Amsterdam from
April 24-28, 201...
Source: Merck.com - Product News - April 8, 2013 Category: Drugs & Pharmacology Authors: hq_site_admin Tags: Prescription Medicine News Corporate News Source Type: news
